These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25284585)

  • 1. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
    Dillon LM; Bean JR; Yang W; Shee K; Symonds LK; Balko JM; McDonald WH; Liu S; Gonzalez-Angulo AM; Mills GB; Arteaga CL; Miller TW
    Oncogene; 2015 Jul; 34(30):3968-76. PubMed ID: 25284585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
    Ebi H; Costa C; Faber AC; Nishtala M; Kotani H; Juric D; Della Pelle P; Song Y; Yano S; Mino-Kenudson M; Benes CH; Engelman JA
    Proc Natl Acad Sci U S A; 2013 Dec; 110(52):21124-9. PubMed ID: 24327733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 (P-Rex-1), a guanine nucleotide exchange factor for Rac, mediates angiogenic responses to stromal cell-derived factor-1/chemokine stromal cell derived factor-1 (SDF-1/CXCL-12) linked to Rac activation, endothelial cell migration, and in vitro angiogenesis.
    Carretero-Ortega J; Walsh CT; Hernández-García R; Reyes-Cruz G; Brown JH; Vázquez-Prado J
    Mol Pharmacol; 2010 Mar; 77(3):435-42. PubMed ID: 20018810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
    Hampsch RA; Shee K; Bates D; Lewis LD; Désiré L; Leblond B; Demidenko E; Stefan K; Huang YH; Miller TW
    Oncotarget; 2017 Mar; 8(13):21806-21817. PubMed ID: 28423521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.
    Montero JC; Seoane S; Pandiella A
    Cell Signal; 2013 Nov; 25(11):2281-9. PubMed ID: 23899556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
    Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
    Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rac signaling in breast cancer: a tale of GEFs and GAPs.
    Wertheimer E; Gutierrez-Uzquiza A; Rosemblit C; Lopez-Haber C; Sosa MS; Kazanietz MG
    Cell Signal; 2012 Feb; 24(2):353-362. PubMed ID: 21893191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner.
    Felekkis KN; Narsimhan RP; Near R; Castro AF; Zheng Y; Quilliam LA; Lerner A
    Mol Cancer Res; 2005 Jan; 3(1):32-41. PubMed ID: 15671247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Phosphatidylinositol (3,4,5)-Trisphosphate-dependent Rac Exchanger 1·Ras-related C3 Botulinum Toxin Substrate 1 (P-Rex1·Rac1) Complex Reveals the Basis of Rac1 Activation in Breast Cancer Cells.
    Lucato CM; Halls ML; Ooms LM; Liu HJ; Mitchell CA; Whisstock JC; Ellisdon AM
    J Biol Chem; 2015 Aug; 290(34):20827-20840. PubMed ID: 26112412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.
    Kim EK; Yun SJ; Ha JM; Kim YW; Jin IH; Yun J; Shin HK; Song SH; Kim JH; Lee JS; Kim CD; Bae SS
    Oncogene; 2011 Jun; 30(26):2954-63. PubMed ID: 21339740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) Activity Promotes Breast Cancer Cell Proliferation and Tumor Growth via Activation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Signaling.
    Liu HJ; Ooms LM; Srijakotre N; Man J; Vieusseux J; Waters JE; Feng Y; Bailey CG; Rasko JE; Price JT; Mitchell CA
    J Biol Chem; 2016 Aug; 291(33):17258-70. PubMed ID: 27358402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration.
    Hernández-Negrete I; Carretero-Ortega J; Rosenfeldt H; Hernández-García R; Calderón-Salinas JV; Reyes-Cruz G; Gutkind JS; Vázquez-Prado J
    J Biol Chem; 2007 Aug; 282(32):23708-15. PubMed ID: 17565979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
    Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
    Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of P-Rex1 for its role in fMet-Leu-Phe-induced superoxide production in reconstituted COS(phox) cells.
    Nie B; Cheng N; Dinauer MC; Ye RD
    Cell Signal; 2010 May; 22(5):770-82. PubMed ID: 20074642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis.
    Qin J; Xie Y; Wang B; Hoshino M; Wolff DW; Zhao J; Scofield MA; Dowd FJ; Lin MF; Tu Y
    Oncogene; 2009 Apr; 28(16):1853-63. PubMed ID: 19305425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cAMP-dependent activation of the Rac guanine exchange factor P-REX1 by type I protein kinase A (PKA) regulatory subunits.
    Adame-García SR; Cervantes-Villagrana RD; Orduña-Castillo LB; Del Rio JC; Gutkind JS; Reyes-Cruz G; Taylor SS; Vázquez-Prado J
    J Biol Chem; 2019 Feb; 294(7):2232-2246. PubMed ID: 30530493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.